Form 4: Arbutus Biopharma Director Reports Stock Transaction
Insider Transaction (Form 4)
Roger Sawhney, a Director of Arbutus Biopharma Corp, reported multiple transactions in common stock on September 18, 2026.
Summary
- Option exercise/conversion: acquired 52,533 Common Shares at $3.34 ($175,460) on September 18, 2026; holds 52,533 after (Direct).
- Option exercise/conversion: acquired 78,800 Common Shares at $4.24 ($334,112) on September 18, 2026; holds 131,333 after (Direct).
- Tax/exercise-price withholding: disposed of 100,508 Common Shares at $5.07 ($509,576) on September 18, 2026; holds 30,825 after (Direct).
- Option exercise/conversion: disposed of 52,533 Stock Option (Right to Buy) on September 18, 2026; holds 105,067 after (Direct).
- Option exercise/conversion: disposed of 78,800 Stock Option (Right to Buy) on September 18, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Roger Sawhney — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Option exercise/conversion | Common Shares | 52,533 | $3 | $175.5K | 52,533 |
| 2026-09-18 | Option exercise/conversion | Common Shares | 78,800 | $4 | $334.1K | 131,333 |
| 2026-09-18 | Tax/exercise-price withholding | Common Shares | 100,508 | $5 | $509.6K | 30,825 |
| 2026-09-18 | Option exercise/conversion | Stock Option (Right to Buy) | 52,533 | — | — | 105,067 |
| 2026-09-18 | Option exercise/conversion | Stock Option (Right to Buy) | 78,800 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Option exercise/conversion (52,533 shares) |
| 2026-09-18 | Option exercise/conversion (78,800 shares) |
| 2026-09-18 | Tax/exercise-price withholding (100,508 shares) |
| 2026-09-18 | Option exercise/conversion (52,533 shares) |
| 2026-09-18 | Option exercise/conversion (78,800 shares) |
Keywords
insider transaction, Form 4, ABUS, Arbutus Biopharma Corp, neutral, Roger Sawhney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.